The CLK4 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the dual-specificity kinase CLK4 in the human Raji B lymphocyte cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated disruption of the CLK4 gene, providing a powerful tool for investigating CLK4-dependent regulatory mechanisms in B-cell biology and oncogenesis without predefined clonal selection.
The Raji cell line is an Epstein-Barr virus (EBV)-positive lymphoblastoid line derived from a Burkitt lymphoma patient. As a widely used B lymphocyte model, Raji cells recapitulate key features of B-cell malignancies, including aberrant proliferation and survival signaling. Their established use in immunological and cancer research makes them an ideal host for studying gene function in the context of B-cell lymphoma pathogenesis and therapeutic intervention.
CLK4 functions as a nuclear dual-specificity kinase that phosphorylates serine/arginine-rich (SR) proteins, including SRSF1, SRSF2, SRSF3, SRSF4, SRSF5, and SRSF6, thereby controlling alternative pre-mRNA splicing. CLK4 activity is regulated by upstream signals such as epidermal growth factor receptor (EGFR) and the PI3K/AKT signaling cascade, as well as by cellular stress responses. It directly interacts with SR proteins, other CLK family members, and spliceosomal components, forming part of the intricate network that governs splice site selection. Through phosphorylation of SR proteins, CLK4 modulates the inclusion or skipping of exons in target mRNAs, ultimately influencing the expression of splice variants involved in cell cycle progression, proliferation, and apoptosis.
In Raji B lymphocytes, CLK4-mediated alternative splicing is particularly relevant to Burkitt lymphoma pathology. Disruption of CLK4 is expected to alter the splicing patterns of genes that regulate critical oncogenic processes, potentially affecting pathways such as MYC-driven proliferation and B-cell receptor signaling. This polyclonal knockout population enables researchers to dissect how CLK4-dependent splicing events contribute to lymphoma maintenance, transformation, and drug resistance within a well-characterized B-cell context.
This product is suitable for a broad range of experimental applications, including the study of splicing regulation in lymphoma, validation of CLK4 as a therapeutic target, and functional analysis of splice site selection. Researchers can employ it in RNA-sequencing experiments to profile differential splicing events, RT-PCR assays to quantify specific splice variants, Western blotting to assess CLK4 and phosphorylated SR protein levels, and kinase activity assays to evaluate enzymatic function. Cell-based assays such as proliferation and apoptosis measurements, as well as immunofluorescence localization studies, can further elucidate the cellular consequences of CLK4 loss. For additional information or to discuss custom requirements, please contact Ascent Research.
